Medicenna Therapeutics Corp.

Hello, and welcome to the Medicine and Therapeutics Fiscal Second Quarter Earnings Call. All participants are now in a listen-only mode. There will be a Q&A session at the end of the prepared remarks. Please be advised this call is being recorded at the company's request. I would now like to turn the call over to Dan Ferry of LifeSciAdvisors.

Please go ahead.

Thank you, Operator, and thank you all for participating in today's conference call. This morning, Medicina issued a press release providing financial results and corporate updates for the quarter ended September 30th, 2022. If you have not yet seen the press release, it is available on the investor page of Medicina's website. Before we begin, I would like to remind you that certain statements and information shared during this call constitute forward-looking information within the meaning of applicable securities laws. All statements other than statements of historical facts shared during this call and that relate to the future operations of the company and other statements that are not historical facts, including statements related to the clinical potential and development of MDNA 11, preliminary clinical data, cash runway, and the presentation of additional data and other milestones are forward-looking statements that are subject to risks and uncertainties. There could be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that may cause actual results to differ materially from the company's expectations include the risk detailed in the annual information form, management's discussion analysis, and form 20F of the company and in other filings made by the company with the applicable securities regulators from time to time in Canada and the United States. Listeners are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the company. You are cautioned not to place undue reliance on any forward-looking information, such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this conference call are expressly qualified by this cautionary statement. Except as required by law, the company does not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements only as expressly required by Canadian and United States securities law. Speaking on today's call will be Medicine's President and Chief Executive Officer, Dr. Fahar Merchant, and Chief Financial Officer, Liz Williams. I will now turn the call over to Fahar to begin. Fahar?